April 17, 2014 6:34 PM ET

Healthcare Equipment and Supplies

Company Overview of AngioScore, Inc.

Company Overview

AngioScore, Inc. designs, develops, manufactures, and markets scoring balloon catheters to treat cardiovascular and peripheral artery diseases. It offers AngioSculpt EX, a coronary scoring device; and AngioSculpt PTCA, a scoring balloon catheter for the treatment of coronary arteries. The company also provides AngioSculpt PTA scoring balloon catheter for treating peripheral artery diseases. Its products are used to treat dilatation of lesions in the iliac, femoral, ilio-femoral, popliteal, infra popliteal, and renal arteries; and for the treatment of obstructive lesions of native or synthetic arteriovenous dialysis fistulae. The company provides its products through direct sales in the Unite...

5055 Brandin Court

Fremont, CA 94538

United States

Founded in 2003

Phone:

510-933-7900

Fax:

510-933-7901

Key Executives for AngioScore, Inc.

Co-Founder
Age: 65
Co-Founder and Chief Medical Officer
Age: 57
Chief Financial Officer and Senior Vice President
Senior Vice President of Operations
Age: 53
Managing Director of International Business
Compensation as of Fiscal Year 2013.

AngioScore, Inc. Key Developments

AngioScore, Inc. Presents at The JPMorgan 32nd Annual Healthcare Conference, Jan-15-2014 11:30 AM

AngioScore, Inc. Presents at The JPMorgan 32nd Annual Healthcare Conference, Jan-15-2014 11:30 AM. Venue: Westin St. Francis Hotel, 335 Powell Street, San Francisco, CA 94102, United States. Speakers: Thomas R. Trotter, Co-Founder, Chief Executive Officer, President and Director.

AngioScore Announces Preliminary Clinical Trial Results for the World's First Drug-Coated Scoring Balloon Catheter

AngioScore, Inc. announced detailed preliminary clinical trial results for the world's first drug-coated scoring balloon catheter. This First-in-Human (FIH) trial of a novel drug-coated AngioSculpt PTCA Scoring Balloon Catheter, known by the acronym PATENT-C, enrolled 61 patients with coronary in-stent restenosis (ISR) at five renowned international sites, four in Germany and one in Brazil. The study was led by Bruno Scheller, M.D., Professor of Interventional Cardiology at Saarland University Hospital, Homburg, Germany, who along with Professor Ulrich Speck of the Charite Hospital in Berlin, is one of the preeminent pioneers in the rapidly developing field of drug-coated balloons for the treatment of coronary and peripheral artery disease. The PATENT-C study was designed as a randomized controlled trial comparing the recently developed drug-coated AngioSculpt with the commercially available uncoated version of the AngioSculpt in patients presenting with significant restenosis in a previously implanted coronary bare metal stent.

AngioScore, Inc. Announces Preliminary Data from the First-In-Human Study of the Drug-Coated AngioSculpt(R) Scoring Balloon Catheter

AngioScore, Inc. announced that preliminary data from the First-In-Human (FIH) Study (PATENT-C) of the Drug-Coated AngioSculpt Scoring Balloon Catheter will be presented at the Transcatheter Cardiovascular Therapeutics (TCT) Conference in San Francisco the week of October 28, 2013. This FIH trial of a novel drug-coated scoring balloon catheter enrolled 61 patients with coronary in-stent restenosis (ISR) at five renowned international sites, four in Germany and one in Brazil. The study was led by Bruno Scheller, M.D., Professor of Interventional Cardiology at Saarland University Hospital, Homburg, Germany, who, along with Professor Ulrich Speck of the Charite Hospital in Berlin, is one of the preeminent pioneers in the rapidly developing field of drug-coated balloons for the treatment of coronary and peripheral artery disease. The drug-coated AngioSculpt FIH study was designed as a randomized controlled trial comparing the recently developed drug-coated AngioSculpt with the commercially available uncoated version of the AngioSculpt in patients presenting with significant restenosis in a previously implanted coronary bare metal stent. Patients underwent follow-up coronary angiography at six months to compare the rate of recurrent restenosis and late lumen loss (LLL) in both treatment arms. Additional study endpoints include the rate of major adverse cardiovascular events (MACE), clinically driven target lesion revascularization (TLR) and stent thrombosis for up to two years following the index procedure. All angiograms were analyzed by an independent core laboratory at the Cardiovascular Research Foundation in New York, N.Y. The AngioSculpt Scoring Balloon Catheters represent the next generation in angioplasty catheters for both coronary and peripheral artery disease. The AngioSculpt catheters provide the versatility and effectiveness of a new technology together with the simplicity and deliverability of traditional high-performance balloon catheters. AngioSculpt catheters have now been used in more than 300,000 procedures worldwide and have achieved an outstanding safety and performance record in the treatment of both coronary and peripheral artery disease. The Drug-Coated AngioSculpt Scoring Balloon Catheter is an investigational device, limited by applicable law to investigational use and not available for sale.

Similar Private Companies By Industry

Company Name Region
Reliant Healthcare Solutions, Inc. United States
Vultus Orthodontic Technologies LLC United States
Conventus Orthopaedics, Inc. United States
JCF Engineering, Inc. United States
Tillotson Corporation United States

Recent Private Companies Transactions

Type
Date
Target
No transactions available in the past 12 months.
 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
NYC2012, Inc. United States
Lawyers Committee for Civil Rights Under Law United States
Bertelsmann AG Europe
Rush University United States
Greater Houston Partnership United States

Post a JobJobs

View all jobs

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact AngioScore, Inc., please visit www.angioscore.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.